Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.

2.

Phase II trial of sorafenib in advanced thyroid cancer.

Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS.

J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.

3.

Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration.

Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, Pearce W, Meek S, Millan J, Cutillas PR, Smith AJ, Ridley AJ, Ruhrberg C, Gerhardt H, Vanhaesebroeck B.

Nature. 2008 May 29;453(7195):662-6. doi: 10.1038/nature06892. Epub 2008 Apr 30.

PMID:
18449193
4.

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

Stauffer F, Maira SM, Furet P, García-Echeverría C.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1027-30. doi: 10.1016/j.bmcl.2007.12.018. Epub 2007 Dec 15.

PMID:
18248814
5.

A quantitative analysis of kinase inhibitor selectivity.

Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP.

Nat Biotechnol. 2008 Jan;26(1):127-32. doi: 10.1038/nbt1358.

PMID:
18183025
6.

Cancer: mixing cocktails.

Sawyers CL.

Nature. 2007 Oct 25;449(7165):993-6. No abstract available.

PMID:
17960228
7.

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA.

Science. 2007 Oct 12;318(5848):287-90. Epub 2007 Sep 13.

8.

A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.

Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA.

Cancer Res. 2007 Sep 1;67(17):7960-5.

9.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA.

Science. 2007 May 18;316(5827):1039-43. Epub 2007 Apr 26.

10.

Chemically targeting the PI3K family.

Knight ZA, Shokat KM.

Biochem Soc Trans. 2007 Apr;35(Pt 2):245-9.

PMID:
17371250
11.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

12.

Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.

Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS.

Cancer Res. 2006 Aug 15;66(16):7864-9.

13.

Rational design of inhibitors that bind to inactive kinase conformations.

Liu Y, Gray NS.

Nat Chem Biol. 2006 Jul;2(7):358-64.

PMID:
16783341
14.

Mechanisms of drug inhibition of signalling molecules.

Sebolt-Leopold JS, English JM.

Nature. 2006 May 25;441(7092):457-62. Review.

PMID:
16724058
15.

Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Shaw RJ, Cantley LC.

Nature. 2006 May 25;441(7092):424-30. Review.

PMID:
16724053
16.

A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, Shokat KM, Weiss WA.

Cancer Cell. 2006 May;9(5):341-9.

17.

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM.

Cell. 2006 May 19;125(4):733-47. Epub 2006 Apr 27.

18.

BAY 43-9006 inhibition of oncogenic RET mutants.

Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M.

J Natl Cancer Inst. 2006 Mar 1;98(5):326-34.

PMID:
16507829
19.

Can we rationally design promiscuous drugs?

Hopkins AL, Mason JS, Overington JP.

Curr Opin Struct Biol. 2006 Feb;16(1):127-36. Epub 2006 Jan 25. Review.

PMID:
16442279
20.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS.

N Engl J Med. 2005 Nov 10;353(19):2012-24. Erratum in: N Engl J Med. 2006 Feb 23;354(8):884.

Supplemental Content

Support Center